The FDA

News and Video Search Results

News coverage

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, and QuidelOrtho and Encourages Investors to Contact the Firm

GlobeNewswire 20 Apr 2024

NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm,..

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 19 Apr 2024
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
GlobeNewswire 19 Apr 2024
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
GlobeNewswire 19 Apr 2024
CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US
PR Newswire Asia 19 Apr 2024

0 shares 2 views

You might like

The FDA media coverage

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)

GlobeNewswire 19 Apr 2024

LOS ANGELES, April 19, 2024 (GLOBE NEWSWIRE) --Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming *May 28,..

The Global Market for HPV Associated Disorders, 2018-2023 and 2024-2033, Featuring Profiles of Leading Players AstraZeneca, Roche, Biocon, GlaxoSmithKline, and Merck & Co
GlobeNewswire 19 Apr 2024
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
GlobeNewswire 19 Apr 2024
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
GlobeNewswire 19 Apr 2024
3Daughters Named “Startup of the Year” at BioLabs Philadelphia Investor Day 2024
GlobeNewswire 19 Apr 2024

Advertisement

More coverage

GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer

PR Newswire Asia 19 Apr 2024

SHANGHAI, April 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge..